Medgend Icon

Ledgend of Medicine







discontinued


Disease

Creutzfeldt-Jakob disease (CJD) is a rare, degenerative brain disorder. Symptoms usually start around age 60. Memory problems, behavior changes, vision problems, and poor muscle coordination progress quickly to dementia, coma, and death. Most patients die within a year.

The three main categories of CJD are :

  • Sporadic CJD, which occurs for no known reason
  • Hereditary CJD, which runs in families
  • Acquired CJD, which occurs from contact with infected tissue, usually during a medical procedure

Cattle can get a disease related to CJD called bovine spongiform encephalopathy (BSE) or "mad cow disease." There is concern that people can get a variant of CJD from eating beef from an infected animal, but there is no direct proof to support this.

NIH: National Institute of Neurological Disorders and Stroke

Disease FDA Approved Drugs

ACCUNEB [Albuterol Sulfate2C13H21NO3H2O4S]
RX
-
eq 0.021% base (inhalation solution)
eq 0.042% base (inhalation solution)
Mylan Speciality LpApr 30, 2001
  • Indicated for the relief of bronchospasm in patients 2-12 years of age with asthma (reversible obstructive airway disease).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ALTOPREV [LovastatinC24H36O5]
RX
-
20mg (oral tablet, extended release)
40mg (oral tablet, extended release)
60mg (oral tablet, extended release)
Covis Pharma BvJun 26, 2002
  • Method of decreasing the production of a-beta using a composition which decreases blood cholesterol in patients at risk of or exhibiting symptoms of alzheimer's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ALVESCO [CiclesonideC32H44O7]
RX
-
0.08mg/inh (inhalation aerosol, metered)
0.16mg/inh (inhalation aerosol, metered)
Takeda GmbhJan 10, 2008
  • Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child.
  • Method of treating inflammatory conditions.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ANORO ELLIPTA [Umeclidinium BromideC29H34NO2Br : Vilanterol TrifenatateC24H33Cl2NO5C20H16O2]
RX
-
eq 0.0625mg base/inh : eq 0.025mg base/inh (inhalation powder)
GlaxosmithklineDec 18, 2013
  • Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema..
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ARCAPTA NEOHALER [Indacaterol MaleateC24H28N2O3C4H4O4]
RX
-
eq 75mcg base (inhalation powder)
Sunovion Pharms IncJul 1, 2011
  • The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ASPIRIN [AspirinC9H8O4]
Plx PharmaJan 14, 2013
  • Temporary reduction of fever.
  • Temporary relief of minor aches and pains.
  • Treatment/prevention of cardiovascular disease.
efficacy
4.1  (12)
side effects
2.0  (2)
danger
2.5  (4)

UNK

AUSTEDO [DeutetrabenazineC19H27NO3]
RX
-
12mg (oral tablet)
6mg (oral tablet)
9mg (oral tablet)
Teva Branded PharmApr 3, 2017
  • Treatment of a neurodegenerative disease or a symptom thereof.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

AZILECT [Rasagiline MesylateC12H13NCH4O3S]
RX
-
eq 0.5mg base (oral tablet)
eq 1mg base (oral tablet)
TevaMay 16, 2006
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BEVESPI AEROSPHERE [Formoterol Fumarate2C19H24N2O4C4H4O42H2O : GlycopyrrolateC19H28NO3Br]
RX
-
0.0048mg/inh : 0.0090mg/inh (inhalation aerosol, metered)
Astrazeneca PharmsApr 25, 2016
  • Use in the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BRILINTA [TicagrelorC23H28F2N6O4S]
RX
-
60mg (oral tablet)
90mg (oral tablet)
Astrazeneca PharmsSep 3, 2015
  • Method of inhibiting platelet aggregation.
  • Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction.
  • Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Reduction of the rate of thrombotic events in patients with acute coronary syndrome.
  • Treatment of an arterial thrombotic complication in a patient with coronary artery, cerebrovascular or peripheral vascular disease.
  • Treatment of arterial thrombotic complications selected from the group consisting of unstable angina, thrombotic or embolic stroke, transient ischaemic attacks, peripheral vascular disease and myocardial infarction.
  • Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of myocardial infarction.
  • Treatment of post-myocardial infarction.
  • Treatment of stable and unstable angina.
  • Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of stroke.
  • Treatment of thrombotic stroke.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BROVANA [Arformoterol TartrateC19H24N2O4C4H6O6]
RX
-
eq 0.015mg base/2ml (inhalation solution)
SunovionOct 6, 2006
  • For the long term treatment, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CARNITOR [LevocarnitineC7H15NO3]
RX
-
1gm/10ml (oral solution)
200mg/ml (injection injectable)
330mg (oral tablet)
Leadiant Biosci IncApr 10, 1986
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CERDELGA [Eliglustat Tartrate2C23H36N2O4C4H6O6]
RX
-
eq 84mg base (oral capsule)
Genzyme CorpAug 19, 2014
  • Treatment of gaucher disease type 1.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

COMTAN [EntacaponeC14H15N3O5]
RX
-
200mg (oral tablet)
Orion PharmaOct 19, 1999
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CRESTOR [Rosuvastatin Calcium2C22H27FN3O6SCa]
RX
-
10mg (oral tablet)
20mg (oral tablet)
40mg (oral tablet)
5mg (oral tablet)
IprAug 12, 2003
  • Treatment of pediatric patients 8 to 17 years of age with heterozygous familial hypercholesterolemia (hefh).
  • Use of rosuvastatin calcium for the primary prevention of cardiovascular disease in individuals without clinically evident coronary heart disease but with increased risk factors.
  • Use of rosuvastatin calcium to reduce elevated total-c, ldl-c, apob, nonhdl-c or tg levels; to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia; and to slow the progression of atherosclerosis..
efficacy
4.5  (2)
side effects
1.0  (1)
danger
1.0  (1)

UNK

DEXILANT [DexlansoprazoleC16H14F3N3O2S]
RX
-
30mg (oral capsule, delayed release)
60mg (oral capsule, delayed release)
Takeda Pharms UsaJan 30, 2009
  • For healing of all grades of erosive esophagitis (ee).
  • For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd).
  • Healing of all grades of erosive esophagitis (ee) for up to 8 weeks.
  • Maintain healing of erosive esophagitis (ee) for up to 6 months.
  • To maintain healing of ee and relief of heartburn.
  • Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks.
  • Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DEXILANT SOLUTAB [DexlansoprazoleC16H14F3N3O2S]
RX
-
30mg (oral tablet, orally disintegrating, delayed release)
Takeda Pharms UsaJan 26, 2016
  • Maintain healing of erosive esophagitis (ee) for up to 6 months.
  • Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ELELYSO [Taliglucerase Alfa]
RX
-
200 units/vial (iv (infusion) powder)
PfizerMay 1, 2012
  • A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide..
  • A method of treating gaucher's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FASLODEX [FulvestrantC32H47F5O3S]
RX
-
50mg/ml (intramuscular injectable)
AstrazenecaApr 25, 2002
  • Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
  • Treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbococlib in women with disease progression after endocrine therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FOSRENOL [Lanthanum Carbonate3CO32LaH2O]
RX
-
eq 1gm base (oral powder)
eq 500mg base (oral tablet, chewable)
eq 750mg base (oral powder)
Shire Dev LlcSep 24, 2014
Shire LlcNov 23, 2005
  • To reduce serum phosphate in patients with end stage renal disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

GILENYA [FingolimodC19H33NO2]
RX
-
0.5mg (oral capsule)
NovartisSep 21, 2010
  • Treatment of autoimmune disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

GILOTRIF [Afatinib DimaleateC24H25ClFN5O32C4H4O4]
RX
-
eq 20mg base (oral tablet)
eq 30mg base (oral tablet)
eq 40mg base (oral tablet)
Boehringer IngelheimJul 12, 2013
  • Treatment of cancer.
  • Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

GLEEVEC [Imatinib MesylateC29H31N7OCH4O3S]
RX
-
eq 100mg base (oral tablet)
eq 400mg base (oral tablet)
NovartisApr 18, 2003
  • A method for treating a tumor disease.
  • Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist).
  • Treatment of gastrointestinal stromal tumors (gist).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

IBRANCE [PalbociclibC24H29N7O2]
RX
-
100mg (oral capsule)
125mg (oral capsule)
75mg (oral capsule)
Pfizer IncFeb 3, 2015
  • Treating hr-pos., her2-neg. advanced or metastatic breast cancer with palbociclib in combo with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression after endocrine therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

INCRUSE ELLIPTA [Umeclidinium BromideC29H34NO2Br]
RX
-
eq 62.5mcg base/inh (inhalation powder)
Glaxo Grp EnglandApr 30, 2014
  • Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema..
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

KENGREAL [CangrelorC17H25Cl2F3N5O12P3S2]
RX
-
50mg/vial (iv (infusion) powder)
Chiesi Usa IncJun 22, 2015
  • Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci.
  • P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

KYPROLIS [CarfilzomibC40H57N5O7]
RX
-
30mg/vial (intravenous powder)
60mg/vial (intravenous powder)
Onyx TherapJun 3, 2016
  • Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

MARQIBO KIT [Vincristine SulfateC46H56N4O10H2O4S]
RX
-
5mg/5ml (1mg/ml) (intravenous injectable, liposomal)
Talon TherapAug 9, 2012
  • Treatment of adult patients with philadelphia chromosome-negative(ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

MIRAPEX ER [Pramipexole DihydrochlorideC10H17N3S2ClHH2O]
RX
-
0.375mg (oral tablet, extended release)
0.75mg (oral tablet, extended release)
1.5mg (oral tablet, extended release)
2.25mg (oral tablet, extended release)
3.75mg (oral tablet, extended release)
3mg (oral tablet, extended release)
4.5mg (oral tablet, extended release)
Boehringer IngelheimFeb 19, 2010
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

MULTAQ [Dronedarone HydrochlorideC31H44N2O5SClH]
RX
-
eq 400mg base (oral tablet)
Sanofi Aventis UsJul 1, 2009
  • Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af.
  • Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a daily with morning and evening meals.
  • Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
  • Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
  • Reduction of the risk of cardiovascular hospitalization.
  • Reduction of the risk of hospitalization for atrial fibrillation.
  • Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NEUPRO [RotigotineC19H25NOS]
RX
-
1mg/24hr (transdermal film, extended release)
2mg/24hr (transdermal film, extended release)
3mg/24hr (transdermal film, extended release)
4mg/24hr (transdermal film, extended release)
6mg/24hr (transdermal film, extended release)
8mg/24hr (transdermal film, extended release)
Ucb IncApr 2, 2012
  • A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient.
  • Treatment of restless legs syndrome by application of claimed transdermal delivery system.
  • Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NEXIUM [Esomeprazole Magnesium2C17H18N3O3SMg3H2O]
RX
-
eq 10mg base/packet (oral for suspension, delayed release)
eq 2.5mg base/packet (oral for suspension, delayed release)
eq 20mg base (oral capsule, delayed rel pellets)
eq 20mg base/packet (oral for suspension, delayed release)
eq 40mg base (oral capsule, delayed rel pellets)
eq 40mg base/packet (oral for suspension, delayed release)
eq 5mg base/packet (oral for suspension, delayed release)
Astrazeneca PharmsFeb 27, 2008
  • Pediatric use aged 1-11 years, gerd and erosive esophagitis.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NUPLAZID [Pimavanserin Tartrate2C25H34FN3O2C4H6O6]
RX
-
eq 17mg base (oral tablet)
Acadia Pharms IncApr 29, 2016
  • Treatment of a neurodegenerative disease or a symptom thereof.
  • Treatment of hallucinations and delusions associated with parkinson's disease psychosis.
  • Treatment of parkinson's disease psychosis.
  • Treatment of psychosis or a symptom thereof.
  • Treatment of psychosis.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

PERFOROMIST [Formoterol Fumarate2C19H24N2O4C4H4O42H2O]
RX
-
0.02mg/2ml (inhalation solution)
Mylan SpecltMay 11, 2007
  • Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

PRADAXA [Dabigatran Etexilate MesylateC34H41N7O5CH4O3S]
RX
-
eq 110mg base (oral capsule)
eq 150mg base (oral capsule)
eq 75mg base (oral capsule)
Boehringer IngelheimNov 20, 2015
  • Method of reversing the anticoagulant effect of dabigatran using idarucizumab.
  • Prophylaxis or treatment of venous and arterial thrombotic disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

PYLERA [Bismuth Subcitrate Potassium2C6H4O7Bi5K3H2O : MetronidazoleC6H9N3O3 : TetracyclineC22H24N2O8]
RX
-
140mg : 125mg : 125mg (oral capsule)
Forest Labs LlcSep 28, 2006
  • Pylera capsules, in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease to eradicate h. pylori.
  • Treatment of patients with h. pylori infection and duodenal ulcer disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

RAYALDEE [CalcifediolC27H44O2H2O]
RX
-
0.03mg (oral capsule, extended release)
Opko Ireland GlobalJun 17, 2016
  • Administration of 25-hydroxyvitamin d3 by controlled release.
  • Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d.
  • Use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease.
  • Use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4.
  • Use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

RAYOS [PrednisoneC21H26O5]
RX
-
1mg (oral tablet, delayed release)
2mg (oral tablet, delayed release)
5mg (oral tablet, delayed release)
Horizon PharmaJul 26, 2012
  • Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet.
  • Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet.
  • Treatment of pulmonary, gastrointestinal and/or rheumatological diseases or conditions by use of delayed release formulations of 1mg or 2mg prednisone.
  • Treatment of rheumatoid arthritis by delayed release formulation of 1mg or 2mg of prednisone.
  • Treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

REVLIMID [LenalidomideC13H13N3O3]
RX
-
10mg (oral capsule)
15mg (oral capsule)
2.5mg (oral capsule)
20mg (oral capsule)
25mg (oral capsule)
CelgeneDec 27, 2005
  • Treatment of male patient having a disease or condition responsive to a teratogenic drug.
  • Use of revlimid (lenalidomide) for the treatment of mantle cell lymphoma (mcl).
  • Use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds).
  • Use of revlimid (lenalidomide) for the treatment of multiple myeloma.
  • Use of revlimid (lenalidomide) for the treatment of transfusion-dependent anemia in myelodysplastic syndromes (mds).
  • Use of revlimid (lenalidomide) to inhibit the secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha.
  • Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

RYTARY [CarbidopaC10H14N2O4H2O : LevodopaC9H11NO4]
RX
-
23.75mg : 95mg (oral capsule, extended release)
36.25mg : 145mg (oral capsule, extended release)
48.75mg : 195mg (oral capsule, extended release)
61.25mg : 245mg (oral capsule, extended release)
Impax Labs IncJan 7, 2015
  • Method of providing a therapeutically effective and stable median blood plasma level of levodopa.
  • Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
  • Treatment of parkinson's disease.
  • Treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
  • Treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
  • Treatment of post-encephalitic parkinsonism.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SEEBRI [GlycopyrrolateC19H28NO3Br]
RX
-
15.6mcg/inh (inhalation powder)
Sunovion Pharms IncOct 29, 2015
  • Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SPIRIVA [Tiotropium Bromide]
RX
-
eq 0.018mg base/inh (inhalation powder)
Boehringer IngelheimJan 30, 2004
  • Administration of an inhalable powder comprising tiotropium via device.
  • For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.
  • Treatment of chronic obstructive pulmonary disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

STALEVO 100 [CarbidopaC10H14N2O4H2O : EntacaponeC14H15N3O5 : LevodopaC9H11NO4]
RX
-
25mg : 200mg : 100mg (oral tablet)
Orion PharmaJun 11, 2003
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

STALEVO 125 [CarbidopaC10H14N2O4H2O : EntacaponeC14H15N3O5 : LevodopaC9H11NO4]
RX
-
31.25mg : 200mg : 125mg (oral tablet)
Orion PharmaAug 29, 2008
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

STALEVO 150 [CarbidopaC10H14N2O4H2O : EntacaponeC14H15N3O5 : LevodopaC9H11NO4]
RX
-
37.5mg : 200mg : 150mg (oral tablet)
Orion PharmaJun 11, 2003
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

STALEVO 200 [CarbidopaC10H14N2O4H2O : EntacaponeC14H15N3O5 : LevodopaC9H11NO4]
RX
-
50mg : 200mg : 200mg (oral tablet)
Orion PharmaAug 2, 2007
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

STALEVO 50 [CarbidopaC10H14N2O4H2O : EntacaponeC14H15N3O5 : LevodopaC9H11NO4]
RX
-
12.5mg : 200mg : 50mg (oral tablet)
Orion PharmaJun 11, 2003
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

STALEVO 75 [CarbidopaC10H14N2O4H2O : EntacaponeC14H15N3O5 : LevodopaC9H11NO4]
RX
-
18.75mg : 200mg : 75mg (oral tablet)
Orion PharmaAug 29, 2008
  • Treatment of parkinson's disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

STRIVERDI RESPIMAT [Olodaterol HydrochlorideC21H26N2O5ClH]
RX
-
eq 0.0025mg base/inh (inhalation spray, metered)
Boehringer IngelheimJul 31, 2014
  • Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SYMBICORT [Budesonide : Formoterol Fumarate Dihydrate]
RX
-
0.08mg/inh : 0.0045mg/inh (inhalation aerosol, metered)
0.16mg/inh : 0.0045mg/inh (inhalation aerosol, metered)
AstrazenecaJul 21, 2006
  • Use for maintenance treatment of chronic obstructive pulmonary disease.
  • Use for the treatment of asthma in patients 6 years of age and older.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TARCEVA [Erlotinib HydrochlorideC22H23N3O4ClH]
RX
-
eq 100mg base (oral tablet)
eq 150mg base (oral tablet)
eq 25mg base (oral tablet)
Osi PharmsNov 18, 2004
  • First-line treatment of locally advanced unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
  • First-line treatment of metastatic non smal-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test.
  • Maintenance treatment in patients with locally advanced or metastatic nsclc who have not progressed on 1st-line treatment wth platinum-based chemotherapy.
  • Maintenance treatment of patients with locally advanced or metastatic nsclc whose disease has not progressed after four cycles platinum-based chemotherapy.
  • Treatment of locally advanced or metastatic non small-cell lung cancer (nsclc) after failure of at least one prior chemotherapy regimen.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TECFIDERA [Dimethyl FumarateC6H8O4]
RX
-
120mg (oral capsule, delayed release)
240mg (oral capsule, delayed release)
Biogen Idec IncMar 27, 2013
  • Method of treating an autoimmune disease selected from autoimmune polyarthritis and multiple sclerosis but not treating psoriatic arthritis.
  • Method of treating multiple sclerosis.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

THALOMID [ThalidomideC13H10N2O4]
RX
-
100mg (oral capsule)
150mg (oral capsule)
200mg (oral capsule)
CelgeneJan 17, 2003
  • Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl).
  • Approval for marketing only under a special restriction program approved by fda called 'system for thalidomide education and prescribing safety' (s.t.e.p.s.).
  • Maintenance therapy for prevention and supression of the cutaneous manifestations of enl recurrence.
  • Method for delivering a drug to a patient in need of the drug, while avoiding the occurence of an adverse side effect known or suspected of being caused by said drug.
  • Treatment of cutaneous manifestations of erythema nodosum leprosum (enl) in connection with a special program approved by fda called 'system for thalidomide education and prescribing safety' (s.t.e.p.s.).
  • Treatment of male patient having a disease or condition responsive to a teratogenic drug.
  • Use in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma.
  • Use of thalidomide in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.
  • Use of thalidomide in treatment of cutaneous manifestations of erythema nodosum leprosum (enl).
  • Use of thalidomide while preventing the exposure of a fetus or other contraindicated individual to thalidomide.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TUDORZA PRESSAIR [Aclidinium BromideC26H30NO4S2Br]
RX
-
0.4mg/inh (inhalation powder, metered)
Astrazeneca PharmsJul 23, 2012
  • Treatment of chronic obstructive pulmonary disease (copd) or chronic bronchitis.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TYZEKA [TelbivudineC10H14N2O5]
RX
-
600mg (oral tablet)
NovartisOct 25, 2006
  • Treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistant elevations in serum aminotransferases (alt or ast) or histologically active disease.
  • Treatment of chronic hepatitis b in adult patients.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

UTIBRON [GlycopyrrolateC19H28NO3Br : Indacaterol MaleateC24H28N2O3C4H4O4]
RX
-
15.6mcg/inh : 27.5mcg/inh (inhalation powder)
Sunovion Pharms IncOct 29, 2015
  • Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

VENTOLIN HFA [Albuterol Sulfate2C13H21NO3H2O4S]
RX
-
eq 0.09mg base/inh (inhalation aerosol, metered)
GlaxosmithklineApr 19, 2001
  • The treatment or prevention of bronchospasm in adults and children 4 years of age and older with reversible obstructive airways disease and the prevention of exercised-induced bronchospasm in patients 4 years of age and older.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XADAGO [Safinamide MesylateC17H19FN2O2CH4O3S]
RX
-
100mg (oral tablet)
50mg (oral tablet)
Us Worldmeds LlcMar 21, 2017
  • Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XIIDRA [LifitegrastC29H24Cl2N2O7S]
RX
-
5% (ophthalmic solution/drops)
Shire Dev LlcJul 11, 2016
  • Treatment of signs and symptoms of dry eye disease (ded).
  • Treatment of the signs symptoms of dry eye disease (ded).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

YOSPRALA [AspirinC9H8O4 : OmeprazoleC17H19N3O3S]
RX
-
325mg : 40mg (oral tablet, delayed release)
81mg : 40mg (oral tablet, delayed release)
Aralez PharmsSep 14, 2016
  • Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers.
efficacy
4.0  (1)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ZETONNA [CiclesonideC32H44O7]
RX
-
0.037mg/inh (nasal aerosol, metered)
Takeda GmbhJan 20, 2012
  • Method of treating inflammatory conditions.
  • Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for reference only. Many of these treatments may be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field. The owner of this website will not be held liable for any injuries and deaths cause by following any home remedies. We have no control of what is posted.

Home Remedies for Disease

HEARTBURN [gastroesophageal reflux disease]
   Eat a high-fiber diet that include beans.
Mechanism - Fiber helps move food out of the stomach faster reducing reflux.
RudyardKipling | November 5th, 2017

Pile of green beans inside a basket.
efficacy
4.0  (1)
side effects
1.0  (2)
danger
1.0  (1)

UNK

CORONAVIRUS [COVID-19]
   Remdesivir is a novel antiviral drug in the class of nucleotide analogs. It was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections, though it has subsequently also been found to show antiviral activity against other single stranded RNA viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus, Nipah virus, Hendra virus, and coronaviruses.Jose3124 | February 15th, 2020
efficacy
3.2  (6)
side effects
2.0  (3)
danger
1.5  (2)

UNK

CANNOT SLEEP [insomnia]
   Skullcap (Scutellaria spp.), or "mad dog weed", is used as a sedative by people in the Appalachian mountains. Was used by American Indians to treat heart disease, diarrhea, eliminate after-birth and foster menstruation.

Steep 2 teaspoons dried leaves in boiling water for 15 minutes. Drink 3 to 4 cups a day maximum.
Mechanism - flavonoids and essential oil
IvanTurgenev | August 4th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CARDIOVASCULAR DISEASE [Atherosclerosis]
   Olive Oil contains omega-3 and omega-6 fatty acids. Omega-3 are prostaglandins which increase blood flow, reduce inflammation and the formation of blood clots. Three polyphenolic compounds in olive oil, oleuropein, tyrosol and hydroxytyrosol, along with mono-unsaturated fat, may be responsible for preventing LDL cholesterol from being oxidized and sticking to the inner walls of arteries. This is referred to as plaque, which restricts blood flow.
Mechanism - oleuropein, tyrosol, hydroxytyrosol
Sleslie | August 27th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Felter's Materia Medica on Disease

AGARICUS (Amanita muscaria)
   The fungus Amanita muscaria, Persoon; (Agaricus muscarius, Linné.) (Nat. Ord. Fungi.) An extremely poisonous fungus found in the pine forests of... / ...sulphate or nitrate have been mostly employed, are in colliquative night-sweating from debilitating diseases, and profuse sweating in the daytime; and to restrain the excess of urine in polyuria, or s... / ...by Eclectic practitioners. Muscarine is used in atropine and belladonna poisoning, sometimes being employed in place of eserine (physostigmine). 3

APOCYNUM CANNABINUM
   The root of Apocynum cannabinum, Linné (Nat. Ord. Apocynaceae) gathered in autumn after the leaves and fruit have matured. Grows throughout the... / ... to work miracles with it where there are such structural lesions as incurable or malignant organic diseases of the heart, liver, or kidneys. Yet in these conditions, when debility and subcutaneous, w... / ...may be looked for. Under these circumstances we have removed enormous dropsical swellings with it, giving quick relief from dyspnea and3

ARNICA MONTANA
   ... Specific Indications.—“Muscular soreness and pain from strain or overexertion; advanced stage of disease, with marked enfeeblement, weak circulation, and impaired spinal innervation; embarrassed re......h prevails the triad-torpor, debility, and depressed function. In the advanced stages of exhausting diseases, where spinal innervation is poor, control over the sphincters lost, and there is feeble re...3

ASCLEPIAS TUBEROSA
   ...le useful in disorders of adults, especially old persons, asclepias will be most often indicated in diseases of infants and children. While it acts best when strictly indicated, it is almost never con......ictly indicated, it is almost never contraindicated in acute respiratory affections. In acute chest diseases asclepias is useful to control cough, pain, temperature, to favor expectoration, and restor...3

BAPTISIA
   ...sembling the “washings of raw meat or prune juice.” Baptisia is not, as a rule, a remedy in acute diseases showing great activity, but rather for disorders showing marked capillary enfeeblement and ...... an aid in the treatment of diphtheria, but alone should not be relied upon to conquer this vicious disease. When most useful the tissues will be swollen, dusky, or blanched, the secretions free, and ...3

BELLADONNA (Atropa belladonna)ATROP
   The (1) dried root and the (2) dried leaves and tops of Atropa Belladonna, Linné (Nat. Ord. Solanaceae). Europe and Central Asia; also... / ...ectual in general hyperhydrosis and in the colliquative sweating of phthisis and other debilitating diseases. The ointment and liniment may serve a similar purpose. This use of belladonna is less desi...3

BERBERIS (Mahonia) AQUIFOLIUM
   ...c Medicine Berberis. Dose, 1 to 30 drops. Specific Indications.—Syphilitic dyscrasia; chronic skin diseases, with blood dyscrasia with or without syphilitic taint; profusely secreting tumid mucous me......ects are produced in such grave constitutional disorders as syphilis. Certainly the ravages of this disease are lessened under these circumstances and aggravated by general ill-conditions. If then syp......ion chiefly as a remedy for the syphilitic taint. The more chronic the conditions or results of the disease, the more it has been praised. Some claim that if given early it will abort the tertiary sta...3

BRYONIA
   ...n bryonia. It is a remedy for debility and the long train of miseries accompanying it, and in acute diseases it is of first importance as a remedy for pain and inflammation in serous membranes. The br...... In such cases it proves a mainstay during the prolonged fever, and never does the patient harm. In diseases of the respiratory tract and pleura, bryonia heads the list of useful remedies. The well-kn...... long period, to prevent, or to absorb, effusion. In these cases the apathy observed in the febrile diseases is absent, the pain and circulatory excitation throwing the patient into a condition of ner...3

CACTUS (Selenicereus spp.)
   ...n the vessels through the vaso-motor apparatus. The peculiar state of the nervous system in cardiac diseases, calling for cactus, is quite characteristic. There is a marked mental depression, often am......doses it does not appear to weaken the nervous system in the least. The special field for cactus is diseases of the heart. Its influence upon the heart is manifested when the disorder is functional; o...3

CALAMUSACCA4
   The rhizome of Acorus Calamus, Linné (Nat. Ord. Acoraceae). Common in wet and muddy grounds everywhere in the Northern Hemisphere. Dose, 5 to 40... / ...es, as indicated, in abscess cavities, burns and scalds (to lessen scarring), acne, ulcerative skin diseases, vaginitis, cervicitis, endometritis, vaginal abrasions, erosion of the os uteri, non-speci... / ...value in all of the local conditions named it has been much overrated, and its real medicinal worth obscured by extravagant praise.3

CALENDULA
   The florets of Calendula officinalis, Linné (Nat. Ord. Compositae). Southern Europe and the Orient; largely cultivated as a garden flower. Dose,... / ...es, as indicated, in abscess cavities, burns and scalds (to lessen scarring), acne, ulcerative skin diseases, vaginitis, cervicitis, endometritis, vaginal abrasions, erosion of the os uteri, non-speci... / ...value in all of the local conditions named it has been much overrated, and its real medicinal worth obscured by extravagant praise.3

CALUMBA (Jateorhiza palmata)JAPA2
   The root of Jateorhiza palmata (Lamarck), Miers (Nat. Ord. Menispermaceae). A climbing perennial, the Kalumb of the Southeast coast of Africa.... / ...tion is merely impaired, but the appetite remains good. It is largely ineffectual also when organic disease of the stomach prevents the normal outflow of gastric juice. When given, the small doses are... / ...by favoring better digestion, the quality of the blood is improved, hence its value in anemia during convalescence.3

CAMPHORA
   A stearopten (having the nature of a ketone) derived from Cinnamomum Camphora. (Linné), Nees et Ebermeier (Nat. Ord. Lauraceae). China and... / ...l areas. Powdered camphor is an ingredient of tooth powders and pastes and dusting powders for skin diseases. Alone or with zinc oxide, talc, or precipitated chalk it may be used upon bed-sores with d... / ...due to gaseous distention of the stomach, or to nervous irritability. In occipital headache, from mental strain, or overstudy, small doses of 3

CANTHARIS
   The dried beetles, Cantharis vesicatoria (Linné), De Geer. (Ord. Coleoptera.) Southern Europe. Dose, 1 grain. Common Name: Spanish Fly; Synonym:... / ...ened and aggravated and then relieved by it. Its internal use has been advised in some chronic skin diseases, such as psoriasis, prurigo, lichen, and eczema; upon what grounds we are not advised.3

CAPSICUM
   The ripe fruit, dried, of Capsicum frutescens, Linné (Nat. Ord. Solanaceae). Tropical America; also cultivated in most tropical countries. Dose,... / ...h are inactive, no agent is superior nor safer than capsicum. It has, therefore, wide usefulness in disease-acute, subacute, or chronic. For chronic gastric catarrh it may be used occasionally, but sh...3


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Physician's Materia Medica on Disease

ABSCESS-ROOT
   The root of POLEMONIUM REPTANS, Lin. Diaphoretic, especially in the form of hot infusion; expectorant, alterative, astringent. Has been used in febrile and inflammatory diseases, especially of the chest, and as a gargle in pharyngitis, etc.4

ACID BORIC (Boracic Acid)
   Antiseptic, yet non-irritant and not poisonous. Used largely in powder or glycerite as antiseptic dressing for wounds and ulcers; solutions are employed as collyria and for local use in nasal catarrh, ozena, cystitis, gonorrhea and various cutaneous diseases. Internal ly it is prescribed to render the urine acid in cystitis and as a remedy in fermentative dyspepsia. Dose, 0.3 to 1.0 Grm. (5 to 15 grs.).4

ACID TANNIC (Tannin)
   Powerful astringent. Employed locally as a styptic; internally sometimes prescribed in diarrhea, but more commonly drugs rich in Tannin such as Blackberry or Rhatany are used. Dose, 0.12 to 0.6 Grm. (2 to 10 grs.). Ointment Tannic Acid, U. S. P., (87% grs. to the ounce). Used especially in hemorrhoids. Glycerite Tannic Acid, U. S. P. (87% grs. to the ounce). Used as application to throat in relaxed condition, also locally in chronic coryza and ozena, and in certain cutaneous diseases. as eczema,4

AMERICAN IVY (Ampelopsis)
   The bark of the root of PARrrinNOCrssUs QUINQUEFOLIA, (Lin.) Planch. Alterative, tonic, expectorant, astringent. Used in dropsy, in pulmonary diseases and in strumous affectious.4

ARSENIC
   An active irritant poison. In small doses a powerful alterative. tonic, hematinic and antiperiodic. Prescribed in chronic cutaneous diseases, secondary syphilis, chorea, neuralgia and malarial fevers. a. Arsenous Bromide. Has been used especially in diabe tes. Dose, 0.0015 to 0.006 Grm. (1-40 to 1-10 gr.). b. Arsenous Chloride. Dose, 0.002 to 0.004 Grm. (1-30 to 1-15 am). For formulas see in Part II, Alteratives ( a) and Tonics (i). c. Arslenous iodide. Particularly useful in syphilis and obstin4

BITTER-SWEET (Dulcamara)
   The twigs of SOLANUM DULCAMARA, Lin. Feebly narcotic; in small doses stimulates the secretions of the skin and kidneys; reputed anaphrodisiac. Used in cutaneous diseases.4

BLACK ALDER
   The bark of ILBX VERTICILLATA ( L.) Gray. Astringent, bitter tonic, alterative, antiperiodic. Serviceable in cutaneous diseases, in diarrhea and all debilitated conditions; in dyspepsia combined with Golden-seal.4

BOLDOPEBO5
   The leaves of BOLDU BOLDUS,(Mol). Lyons [Peumus Boldus, Mol.]. Aromatic, diuretic, cholagogue, antiseptic; in large doses narcotic and irritant. Prescribed in chronic diseases of the genito-urinary tract, in atonic dyspepsia and as a general tonic.4

BROOM (Scoparlus)CYTIS
   The tops of CvTIsUs ScormuUs, (L.) Link. Diuretic, laxative. in large doses emeto-cathartic. A valuable remedy in dropsies of cardiac origin and in palpitation of the heart due to weakness of the muscular structure or to valvular disease. Active constituent Spar teine, q. v.4

BUCKBEANMENYA
   The leaves of MENYANTHES TRIFOLIATA, Lin. Bitter tonic. alterative, emmenagogue. anthelmintic; in large doses cathartic and emetic. Used in atonic dyspepsia, in chronic cutaneous diseases and in amenorrhea.4


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Physician's Therapeutics Memoranda on Disease

ACNE
   Ascertain whether constitutional disease or disordered dhrestion is present and modify treatment accordingly. Arsenic is generally indicated. especially in... / Ascertain whether constitutional disease or disordered dhrestion is present and modify treatment accordingly. Arsenic is generally indicated. especially in combination with iron. For ... / ...sulphur. sulphur iodide, resor cin, ichthyol or Iodosyl. Give attention to the diet, which should be simple but nourishing. fats especially to be avoided.4

ANOREXIA
   Ascertain and if possible remove cause. In absence of a malarial influence or of local inflammatory disease, prescribe a simple bitter tonic or a mineral acid, with outdoor life and appropriate exercise; Elixir Gentian and Phosphoric Acid. Eupeptic Hypophosphites Elixir Pepsin Compound, B 2, Effewescent Granules Sodium Phos phate are remedies likely to be useful. Lawn Tennis may do more than medicine. and a change of boarding place may be the best prescription of all.4

DROPSY
   General treatment depends on the cause, which may be in disease of the heart, of the kidneys or less commonly of the liver. For im mediate relief prescribe active diuretics if the st ate of the kidneys permits, the most eflicient being Tonic Pilocarpine Compound; digi talis, canadian hemp, squill (these acting primarily on the circula tion), or hydragogue cathartics, elaterium. compound jalap powder, magnesium sulphate (in concentrated solution) are efficient remedies.4

HEART DISEASE
   In organic diseases of the heart. remedies must be adapted to symptoms presented. Digitalis and similar agents are to be used when increase of blood pressure is... / In organic diseases of the heart. remedies must be adapted to symptoms presented. Digitalis and similar agents are to be used when increase of blood pressure is ... / ...arises from debility, general tonics are indicated, particularly nux vomica and iron. In cardiac failure, use diffusible stimulants, ammonia, ether and alcohol.4

INTERMITTENT FEVER
   The prophylaxis consists in destroying the mosquitoes whose bites communicate the disease. Quinine (15 to 30 grains or more) given two hours before the expected chili, is the remedy. This should be given on an empty stomach, and preceded by a cholagogue cathartic. Other remedies of importance are arsenic, methylene blue and the other alkaloids of cinchona bark.4

RACHITIS
   The disease is one of non-assimilation, the remedies, 1st general tonics and nutrients; cod liver oil. quinine, copper arsenite, syrup ferrous iodide, Haemo-Mangan; 2d Bone lood; phosphorus. glycero phosphates, hypophosphites, lacto-phosphates, Eupeptic Hypophos phites, N., B. & Co. Thyroid extract and suprarenal extract have given good results. Improve hygienic condition of patient and prescribe massage and passive exercise when this is practicable.4


References

1) Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.
2) Brooks, Lisa. . Morton Grove: Publications International, 2017.
3) Felter, Harvey Wickes, 1922, The Eclectic Materia Medica, Pharmacology and Therapeutics, Cincinnati, Ohio.
4) Nelson, Baker & Co., 1904, Physician's Handy Book of Materia Medica and Therapeustics, Detroit, Michigan.